Jean-Louis Abitbol

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

GO Capital SAS (GO Capital) is an independent French private equity firm founded 2003 and is headquartered in Saint-Jacques-de-la-Lande. Formerly known as Grand Ouest Gestion SAS, the firm's investors include regional and cooperative banks, Natixis and CDC PME.GO Capital is located in Rennes and focuses primarily on the northwest quarter of France, also known as Grand Ouest, which comprises the Brittany, Poitou-Charentes, Pays de la Loire and Basse Normandie regions. The firm manages the Ouest Ventures fund.

Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Boehringer Ingelheim France SAS engages in the research, development, marketing, and distribution of pharmaceuticals. The company was founded on October 31, 1986 and is headquartered in Paris, France.

Glaxo Wellcome Immobilière de Recherche SA provides real estate services. The company was founded in 1992 and is headquartered in Marly-le-Roi, France.

Loxbridge Research LLP operates as an investment and project management company. It specializes in startup, early stage, and later stage investments in growth stage companies. The firm supports scientists and focuses on sectors like science, medicine and healthcare technology particularly biotech, med-tech, noval therapeutic, diagnostics, cancer, infectious diseases, neurodegeneration, imaging hardware and software, and enabling devices. The company was founded by Charles Roberts in 2008 and is headquartered in London, the United Kingdom.

Part of BioLineRx Ltd., Agalimmune Ltd. is a British company that develops anti-cancer immunotherapy technology. The company is based in London, UK. The company was founded by Charles Campbell Roberts and Graham Griffiths. The CEO is Mike Westby. Agalimmune was acquired by BioLineRx Ltd. on March 23, 2017 for $6.05 million.

Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY.

VitaDx International SAS develops a solution for early diagnosis of bladder cancer. It offers Fluorescence, a technology that can classify cancer cells as tumorous or healthy, and machine learning, a software analysis that used a set of mathematical techniques allowing algorithms to solve problems from data without being explicitly programmed. The company was founded by Allan Rodriguez in 2013 and is headquartered in Rennes, France.

Cytoseek Ltd. provides cell membrane augmentation technology for enhancement of cell therapies for cancer, heart disease, osteoarthritis, and diabetic wound healing. It enables new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. The company was founded by Adam Willis Perriman on November 22, 2017 and is headquartered in Bristol, the United Kingdom.

Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom.

Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022.

Orphan Europe SARL develops and distributes orphan drugs for the treatment of rare diseases. The firm's products include Normosang, Cystagon, Pedea, Carbaglu, Wilzin, Cystadane. The company was founded by William Gunnarsson in 1990 and is headquartered in Puteaux, France.

Pfizer Holding France SCA manufactures and supplies pharmaceutical products. The company was founded in 1961 and is headquartered in Paris, France.